Understanding how two signaling pathways interact in bladder cancer
Dissecting and Targeting MAPK - PPARG Crosstalk in Bladder Cancer
This study is looking at how two important pathways in bladder cancer work together and hopes to find new treatments that could help improve outcomes for patients battling this disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11067846 on NIH RePORTER |
What this research studies
This research investigates the interaction between the MAPK and PPARG signaling pathways in bladder cancer, which is a significant health concern with high rates of diagnosis and mortality. By analyzing genetic alterations in bladder tumors, the study aims to uncover how these pathways contribute to tumor behavior and patient outcomes. The researchers will explore the potential of new therapeutic agents that target these pathways to improve treatment options for patients with bladder cancer. This approach is informed by recent genomic data and aims to provide insights into more effective therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with bladder cancer, particularly those with specific genetic alterations in the MAPK and PPARG pathways.
Not a fit: Patients with non-bladder cancers or those whose tumors do not exhibit alterations in the MAPK or PPARG pathways may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that significantly improve survival rates and quality of life for bladder cancer patients.
How similar studies have performed: Other research has shown promising results in targeting similar pathways in various cancers, indicating that this approach may yield beneficial outcomes.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Mouw, Kent W — Dana-Farber Cancer Inst
- Study coordinator: Mouw, Kent W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.